MetabolismNews.net

Metabolism Xagena

Amgen has announced that the Phase 3 RUTHERFORD-2 ( RedUction of LDL-C with PCSK9 InhibiTion in HEteRozygous Familial HyperchOlesteRolemia Disorder Study-2 ) trial evaluating Evolocumab in combination ...


Current osteoporosis medications increase bone mineral density ( BMD ) modestly and reduce, but do not eliminate, fracture risk. Attempts to improve efficacy by administering anabolic agents and bisph ...


Findings from recent meta-analyses of Vitamin D supplementation without co-administration of calcium have not shown fracture prevention, possibly because of insufficient power or inappropriate doses, ...


The results from a phase 2 trial evaluating Romosozumab in postmenopausal women with low bone mineral density ( BMD ) were published in the New England Journal of Medicine ( NEJM ).The trial demonstra ...


Rhizomelic chondrodysplasia punctata ( RCDP ) is a rare disorder of peroxisomal metabolism, with an estimated incidence of 1:100.000. There are 3 genetic subtypes. RCDP type 1, caused by mutations in ...


Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. A study has assessed the efficacy and safety of the microsomal triglyceride transfer protein ( MTP ) inh ...


Enteral nutrition is recommended for patients in the intensive-care unit ( ICU ), but it does not consistently achieve nutritional goals.Researchers have assessed whether delivery of 100% of the energ ...


Statins are commonly prescribed for management of dyslipidaemia and cardiovascular disease. Increased fitness is also associated with low mortality and is recommended as an essential part of promoting ...


Osteoporosis medications increase bone-mineral density ( BMD ) and lower but do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has not improved efficacy.Researchers ...


Low levels of total 25-Hydroxyvitamin D are common among black Americans. Vitamin D-binding protein ( DBP ) has not been considered in the assessment of vitamin D deficiency.In the Healthy Aging in Ne ...


Arena Pharmaceuticals has officially notified the Committee for Medicinal Products for Human Use ( CHMP ) that it wishes to withdraw its application for a marketing authorisation for Belviq, a medicin ...


The risks of developing kidney failure and a calcium deficiency from osteoporosis drug Zoledronic acid ( Aclasta; Reclast ) are extremely rare, according to researchers at Loyola University Health Sys ...


On 13 December 2012, the Committee for Medicinal Products for Human Use ( CHMP ) has adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Kynam ...


On 18 October 2012, the Committee for Medicinal Products for Human Use ( CHMP ) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Qsiva, int ...


New data have shown that Forteo ( Teriparatide; Forsteo ) significantly increased lumbar spine volumetric bone mineral density ( vBMD ) compared to Risedronate ( Actonel ) in men with glucocorticoid-i ...